Use of in vitro 3D tissue models in genotoxicity testing: Strategic fit, validation status and way forward. Report of the working group from the 7

3D airway models Comet assay DNA damage In vitro genotoxicity testing Liver spheroids Micronucleus test Reconstructed human skin

Journal

Mutation research. Genetic toxicology and environmental mutagenesis
ISSN: 1879-3592
Titre abrégé: Mutat Res Genet Toxicol Environ Mutagen
Pays: Netherlands
ID NLM: 101632149

Informations de publication

Date de publication:
Historique:
received: 09 01 2020
accepted: 09 01 2020
entrez: 6 4 2020
pubmed: 6 4 2020
medline: 25 4 2020
Statut: ppublish

Résumé

Use of three-dimensional (3D) tissue equivalents in toxicology has been increasing over the last decade as novel preclinical test systems and as alternatives to animal testing. In the area of genetic toxicology, progress has been made with establishing robust protocols for skin, airway (lung) and liver tissue equivalents. In light of these advancements, a "Use of 3D Tissues in Genotoxicity Testing" working group (WG) met at the 7

Identifiants

pubmed: 32247552
pii: S1383-5718(20)30005-X
doi: 10.1016/j.mrgentox.2020.503135
pii:
doi:

Substances chimiques

Mutagens 0

Types de publication

Congress Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

503135

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Stefan Pfuhler (S)

Procter and Gamble, Mason Business Centre, Mason, OH, USA. Electronic address: pfuhler.s@pg.com.

Jan van Benthem (J)

National Institute for Public Health and the Environment, Centre for Health Protection, Bilthoven, the Netherlands.

Rodger Curren (R)

Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA.

Shareen H Doak (SH)

Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, Wales, UK.

Maria Dusinska (M)

Health Effects Laboratory, Department of Environmental Chemistry, NILU-Norwegian Institute for Air Research, Kjeller, Norway.

Makoto Hayashi (M)

makoto international consulting, Ebina, Japan.

Robert H Heflich (RH)

U.S. Food and Drug Administration/National Center for Toxicological Research, Jefferson, AR, USA.

Darren Kidd (D)

Covance Laboratories Ltd, Otley Road, Harrogate, HG3 1PY, UK.

David Kirkland (D)

Kirkland Consulting, PO Box 79, Tadcaster, LS24 0AS, UK.

Yang Luan (Y)

School of Public Health, Hongqiao International Institute of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, PR China.

Gladys Ouedraogo (G)

L'Oréal R&I, Aulnay-sous-bois, France.

Kerstin Reisinger (K)

Henkel AG & Co KGaA, Duesseldorf, Germany.

Toshio Sofuni (T)

Formerly National Institute of Health Sciences, Tokyo, Japan.

Frédérique van Acker (F)

Triskelion B.V., Zeist, the Netherlands.

Ying Yang (Y)

Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, PR China.

Raffaella Corvi (R)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH